Hexagon Capital Partners LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Hexagon Capital Partners LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,457 shares of the biopharmaceutical company’s stock after selling 175 shares during the period. Hexagon Capital Partners LLC’s holdings in Gilead Sciences were worth $766,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Altfest L J & Co. Inc. acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $210,000. Federated Hermes Inc. increased its position in Gilead Sciences by 4.9% during the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after purchasing an additional 175,925 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new position in Gilead Sciences during the fourth quarter worth approximately $74,000. Abundance Wealth Counselors acquired a new position in Gilead Sciences during the third quarter worth approximately $1,881,000. Finally, HTLF Bank acquired a new position in Gilead Sciences during the fourth quarter worth approximately $253,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several research analyst reports. Mizuho dropped their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Cantor Fitzgerald dropped their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Royal Bank of Canada dropped their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research report on Friday. Wells Fargo & Company dropped their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Finally, Morgan Stanley dropped their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $83.60.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded down $0.74 on Tuesday, reaching $65.20. 7,433,077 shares of the company’s stock were exchanged, compared to its average volume of 7,480,851. The firm has a market capitalization of $81.18 billion, a price-to-earnings ratio of 181.11, a PEG ratio of 1.29 and a beta of 0.19. Gilead Sciences, Inc. has a fifty-two week low of $64.63 and a fifty-two week high of $87.86. The business’s 50-day moving average is $71.03 and its two-hundred day moving average is $76.08. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the prior year, the company earned $1.37 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 3.82 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.72%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.